An exploratory analysis of glucagon‐like peptide‐1 ( GLP ‐1) agonists and biosimilars: A literature review

Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are at the forefront of treating the global health crisis of diabetes mellitus (DM) and obesity. However, the demand for GLP‐1 RAs has far outstripped its supply and comes with a high monthly cost. Thus, the development of GLP‐1 RA biosimilars can potentially address these barriers by providing greater access to medications that provide clinical outcomes similar to those of the reference products. A narrative review was conducted to examine the current and future developments for GLP‐1 RA biosimilars. Liraglutide and semaglutide are the predominant GLP‐1 RAs being investigated for the development of biosimilars. Preliminary liraglutide biosimilar comparisons to reference liraglutide have demonstrated similar clinical efficacy and safety profiles. Semaglutide and beinaglutide biosimilars are currently under investigation as well. With the growing popularity of GLP‐1 RAs, accessibility and affordability remain a challenge as monthly costs without insurance for liraglutide, semaglutide and tirzepatide are $1418, $892, and $974 respectively. This trend negatively impacts patients with obesity and DM as well as patients who can utilize it for off‐label indications for conditions that benefit from weight loss such as obstructive sleep apnoea and non‐alcoholic fatty liver disease. A substantial number of pharmaceutical and healthcare companies worldwide are conducting clinical trials on their GLP‐1 RA biosimilars. Preliminary results from liraglutide biosimilars are promising, and several semaglutide biosimilars are currently being investigated. Future research should focus on conducting comparative head‐to‐head trials to determine the clinical outcomes between biosimilars and reference products.